>
Organization
Regeneron Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed

News on Regeneron Pharmaceuticals, Inc.

... has taken her from General Electric and Albany Molecular Research Inc. to Regeneron Pharmaceuticals, one of the region's fastest-growing companies. She has worked with employees ...
... that blocks IL-1α and IL-1β signaling. Rilonacept was discovered and developed by Regeneron and is approved by the FDA under the brand name ARCALYST® for ...
... include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's ...
... Regeneron's CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a ...
... activity also seen in ongoing study in diffuse large B-cell lymphoma Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today presented new data for REGN1979 in patients with relapsed ...
... approved for use, including Repatha® (evolocumab) by Amgen and PRALUENT® (alirocumab) by Regeneron/Sanofi. Both of these products are dosed as injections every 2 weeks or ...
... PR Newswire Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast its management presentation at the Piper Jaffray 30th ...
... cohort of OPDIVO® combination trial completed New Phase 2 combination trial with Regeneron's Libtayo® to start 1H 2019 BOSTON, Nov. 16, 2018 (GLOBE NEWSWIRE) -- ...
... growth of the market. Key Vendors Allergan Bayer F. Hoffmann-La Roche Novartis Regeneron Pharmaceuticals Topics Covered For more information about this report visit 12. Vendor ...
... Ziopharm Oncology, Inc., (Nasdaq:ZIOP) today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm's Ad-RTS-hIL-12 plus veledimex in combination with Regeneron's PD-1 ...
Subscribe now for full coverage on Regeneron Pharmaceuticals, Inc.
Start My Free Trial